Chr. Hansen
Chr. Hansen A/S is a bioscience company based in Hørsholm, Denmark. Since January 2024 together with Novozymes a part of Novonesis. The company is a supplier of bacteria cultures, probiotics, enzymes and human milk oligosaccharides. Its products are used in the production of fresh dairy, cheese, meat, seafood, fermented beverages, dairy and meat alternatives, dietary supplements, infant formula, pharmaceuticals and agricultural products. In 2021, Chr. Hansen A/S was ranked 1st on FoodTalks' Top 30 Global Probiotic Food Ingredient Companies list. Chr. Hansen owns one of the world's largest commercial bacteria collections.
| Company type | Publicly traded Aktieselskab |
|---|---|
Traded as | Nasdaq Copenhagen: CHR |
| ISIN | DK0060227585 |
| Industry | Bioscience |
| Founded | 1874 |
| Headquarters | Hørsholm, Denmark |
Key people | Dominique Reiniche (Chair), Mauricio Graber (President and CEO) |
| Products | microbiological cultures, enzymes, probiotics, Human milk oligosaccharides |
| Revenue | €1,218 million (2022) |
| €326 million (2022) | |
Net income | €225 million (2022) |
| Total assets | €3,317 million (2022) |
| Total equity | €181 million |
Number of employees | 3,834 (2021-2022) |
| Website | www.chr-hansen.com |
| Footnotes / references | |
Chr. Hansen A/S has development centers in Denmark, the United States, France and Germany including research facilities in Denmark and France. A large percentage of the employees engage in research and development for the international food and pharmaceuticals industries.
Chr. Hansen A/S has five main production sites: two in Denmark and Germany (Nienburg and Pohlheim) and one each in France (Arpajon) and the US (West Allis, Milwaukee, WI) and an international presence in 30 countries. It has been listed on Nasdaq OMX Copenhagen since June 3, 2010, under the symbol "CHR".